Blue Lake Biotechnology, Inc., a US-based clinical-stage biotechnology company, announced on Monday its preliminary interim data from a phase one clinical trial of its BLB201 vaccine to prevent severe respiratory syncytial virus (RSV)-associated disease (NCT05281263).
The preliminary data were revealed in an oral presentation by Dr Hong Jin, Blue Lake Biotechnology chief scientific officer, at the seventh International Conference on Vaccines Research & Development (Vaccines R&D-2022) in Boston, Massachusetts. Dr Jin revealed that data from the first study cohort indicated that 64% of subjects had increased serum anti-RSV antibody responses above their baseline levels. All participants were seropositive for RSV at baseline. If participants with the highest baseline levels of anti-RSV antibodies are excluded from the evaluation, the proportion of subjects that had increased anti-RSV antibody responses above baseline levels becomes 80%. Temporary shedding of vaccine after vaccination was detected in 21% of participants, indicative of self-limited vaccine replication.
The Phase one clinical trial, a multi-centre, open-label trial, is aimed at assessing the safety, reactogenicity and immunogenicity of a single dose of BLB201 administered as a nasal spray to 30 healthy adults in two sequential age cohorts in the age group of 18 to 59 years and age 60 to 75 years. It is being carried out in Cincinnati Ohio and Charleston South Carolina and headed by Dr Paul Spearman, director of Infectious Diseases at Cincinnati Children's Hospital Medical Center.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine